research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
=== Role in wound healing === Macrophages are essential for wound healing. They replace polymorphonuclear neutrophils as the predominant cells in the wound by day two after injury. Attracted to the wound site by growth factors released by platelets and other cells, monocytes from the bloodstream enter the area through blood vessel walls. Numbers of monocytes in the wound peak one to one and a half days after the injury occurs. Once they are in the wound site, monocytes mature into macrophages. The spleen contains half the body's monocytes in reserve ready to be deployed to injured tissue. The macrophage's main role is to phagocytize bacteria and damaged tissue, and they also debride damaged tissue by releasing proteases. Macrophages also secrete a number of factors such as growth factors and other cytokines, especially during the third and fourth post-wound days. These factors attract cells involved in the proliferation stage of healing to the area. Macrophages may also restrain the contraction phase. Macrophages are stimulated by the low oxygen content of their surroundings to produce factors that induce and speed angiogenesis and they also stimulate cells that re-epithelialize the wound, create granulation tissue, and lay down a new extracellular matrix. By secreting these factors, macrophages contribute to pushing the wound healing process into the next phase.
Most antifreeze is made by mixing distilled water with additives and a base product, usually MEG (mono ethylene glycol) or MPG (mono propylene glycol). Ethylene glycol solutions first became available in 1926 and were marketed as "permanent antifreeze" since the higher boiling points provided advantages for summertime use as well as during cold weather. They are used today for a variety of applications, including automobiles, but there are lower-toxicity alternatives made with propylene glycol available. When ethylene glycol is used in a system, it may become oxidized to five organic acids (formic, oxalic, glycolic, glyoxalic and acetic acid). Inhibited ethylene glycol antifreeze mixes are available, with additives that buffer the pH and preserve alkalinity of the solution to prevent oxidation of ethylene glycol and formation of these acids. Nitrites, silicates, borates and azoles may also be used to prevent corrosive attack on metal. Ethylene glycol has a bitter, sweet taste and causes inebriation. The toxic effects of ingesting ethylene glycol occur because it is converted by the liver into 4 other chemicals that are much more toxic. The lethal dose of pure ethylene glycol is 1.4 ml/kg (3 US fluid ounces (90 ml) is lethal to a 140-pound (64 kg) person) but is much less lethal if treated within an hour. (see Ethylene glycol poisoning).
Tuttle (1857), first bishop of the Episcopal Diocese of Idaho, Montana, and Utah William David Walker (1859), first bishop of the Episcopal Diocese of North Dakota Henry Y. Satterlee (1863), first bishop of the Episcopal Diocese of Washington; established the Washington National Cathedral Bernard Drachman (1882), leader of Orthodox Judaism; former president of the Orthodox Union Leon Harrison (1886), rabbi of Temple Israel in St. Louis Herbert Shipman (1890), Suffragan bishop in the Episcopal Diocese of New York Stephen Samuel Wise (1892), rabbi and Zionist leader Frederick Herbert Sill (1895), Anglican monk and founder of the Kent School Henry S. Whitehead (1904), rector, and author of horror fiction Vedder Van Dyck (1918), fifth bishop in the Episcopal Diocese of Vermont Walter M. Higley (1922), sixth bishop of the Episcopal Diocese of Central New York M. Moran Weston (1930), Episcopal priest, social activist, and businessman who co-founded Carver Federal Savings Bank Arthur Lelyveld (1933), rabbi, president of the American Jewish Congress and first Jewish editor-in-chief of the Columbia Daily Spectator Moshe Davis (1936), rabbi and founder of Camp Ramah Paul van K.
Sources: en.wikipedia.org
The tertiary alcohol tert-amyl alcohol (TAA), also known as 2-methylbutan-2-ol (2M2B), has a history of use as a hypnotic and anesthetic, as do other tertiary alcohols such as methylpentynol, ethchlorvynol, and chloralodol. Unlike primary alcohols like ethanol, these tertiary alcohols cannot be oxidized into aldehyde or carboxylic acid metabolites, which are often toxic, and for this reason, these compounds are safer in comparison. Other relatives of ethanol with similar effects include chloral hydrate, paraldehyde, and many volatile and inhalational anesthetics (e.g., chloroform, diethyl ether, and isoflurane).
== See also == 1970–1979 world oil market chronology 1970s energy crisis 1973 oil crisis 1979 oil crisis 1980s oil glut 2000s energy crisis Economic impact of the 2026 Iran war Global energy crisis (2021–2023) 2025–2026 Russian fuel crisis
Intermediate schools are referred to as "middle schools" in the PGCPS system, and operate as grades 6–8 middle schools. Grades 7–9 junior high school were phased out in the mid-1980s. Recent efforts have been made to convert most middle schools to the more popular grades 6–8 model. Issues in the past such as over-enrollment, lack of classroom space, and funding, had made it hard to convert all middle schools to a grades 6–8 configuration, but with increased funding and the addition of new middle schools, the transition is slowly being made, to be completed by the beginning of SY2024-2025. Most middle schools in Prince George's County operate with a "comprehensive" model, as their base. Most students are assigned to a middle school based on an "attendance area." Most magnet programs operate as a "School-Within-A-School" model, where the magnet serves as an alternative program, in addition to the main comprehensive program, and students from outside the regular attendance area of the middle school are enrolled and accepted into the magnet, either through "continuity" (automatic continuation from an elementary school magnet program to the middle school level equivalent) or more commonly, through a magnet lottery, where students apply for a magnet program and are granted acceptance through a random drawing. Almost all middle schools have a whole-school "Signature Program" that includes a specialized program of instruction which is the foundation of the school's comprehensive program.
Mutations in TCOF1, POLR1C, or POLR1D genes can cause Treacher Collins syndrome. TCOF1 gene mutations are the most common cause of the disorder, with POLR1C and POLR1D gene mutations causing an additional 2% of cases. In individuals without an identified mutation in one of these genes, the genetic cause of the condition is unknown. The TCOF1, POLR1C, and POLR1D genes code for proteins which play important roles in the early development of bones and other tissues of the face. Mutations in these genes reduce the production of rRNA, which may trigger the self-destruction (apoptosis) of certain cells involved in the development of facial bones and tissues. It is unclear why the effects of a reduction in rRNA are limited to facial development. Mutations in TCOF1 and POLR1D cause the autosomal dominant form of Treacher Collins, and mutations in POLR1C cause the autosomal recessive form.
Sources: en.wikipedia.org
The Ten Years' War ended in 1878, and the Spanish government authorized the creation of political parties in Cuba. Most of the leadership of the Grand Lodge of Colon at Havana were founding members of the Autonomist Liberal Party. Antonio Govín y Torres himself became the Secretary of the Autonomist Liberal Party. José María Gálvez became the Party President. Rafael Montoro, the intellectual leader of the party, also served as the Worshipful Master of Logia Plus Ultra (English: Plus Ultra Lodge). Other Freemasons became founding members of the Moderate Party of Cuba. On October 8, 1878, discussions opened on merging the Lodges of Colon Freemasonry and Cuban Freemasonry into a new unified body. The Little War occurred from 1879 to 1880. On either January 25, 1880 or March 25, 1880, the Grand Lodge of Colon at Havana and the Grand Lodge of Cuba, and 46 of their Lodges, merged to become the Gran Logia Unida de Colón y la Isla de Cuba (English United Grand Lodge of Colon and the Island of Cuba). After decades of multiple Grand Lodges and Grand Orients on the island, there was now a single and unified Grand Loge for the entire island of Cuba, with one Grand Master and two Deputy Grand Masters. The United Grand Lodge gained recognition from 34 foreign Masonic bodies. On September 4, 1881, 25 Lodges in Camagüey Province and Oriente Province accepted the authority and joined the United Grand Lodge. In 1881, seventy-one lodges operated in Cuba under the authority of the Grand Lodge.
The National Postgraduate Medical College of Nigeria (NPMCN): Established in 1979, NPMCN is responsible for the training and certification of medical and dental specialists within Nigeria. The West African Postgraduate Medical Colleges: These are the West African College of Physicians (WACP) and the West African College of Surgeons (WACS), which coordinate regional training and certification across West Africa.
== Chemical reactions == Due to its resonance stabilization, the peptide bond is relatively unreactive under physiological conditions, even less than similar compounds such as esters. Nevertheless, peptide bonds can undergo chemical reactions, usually through an attack of an electronegative atom on the carbonyl carbon, breaking the carbonyl double bond and forming a tetrahedral intermediate. This is the pathway followed in proteolysis and, more generally, in N–O acyl exchange reactions such as those of inteins. When the functional group attacking the peptide bond is a thiol, hydroxyl or amine, the resulting molecule may be called a cyclol or, more specifically, a thiacyclol, an oxacyclol or an azacyclol, respectively.
Temgicoluril (INNTooltip International Nonproprietary Name), also known as tetramethylglycoluril and sold under the brand names Adaptol and Mebicar, is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in Latvia and Russia. The chemical structure of temgicoluril is somewhat similar to uric acid and it doesn't interact with acids, alkali, oxidants and reducing agents. It seems to affect all major neurotransmitter systems. Temgicoluril has an effect on the structure of limbic–reticular activity, particularly on hypothalamus emotional zone, as well as on all several basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin, and adrenergic activity. It decreases brain norepinephrine levels and increases brain serotonin levels without modulating dopaminergic systems or cholinergic systems. Temgicoluril purportedly has anti-anxiety (anxiolytic) properties. It is also used to aid smoking cessation. In addition, temgicoluril may be useful in the treatment of ADHD symptoms. In contrast with typical anxiolytic medications such as benzodiazepines, temgicoluril is non-habit forming, non-sedating, and does not impair motor function. It can be prepared by condensation of 1,3-dimethylurea with glyoxal. One publication described such a procedure. They combined dimethylurea and glyoxal with a catalytic amount of phosphoric acid anhydride in an aqueous solution at room temperature and after sufficient time temgicoluril was conveniently isolated by filtration.
The theatre in Brazil has its origins in the period of Jesuit expansion, when theater was used for the dissemination of Catholic doctrine in the 16th century. In the 17th and 18th centuries, dramatists on the scene of European derivation were for court or private performances. During the 19th century, the playwrights Antônio Gonçalves Dias and Luís Carlos Martins Pena were known for their performance. There were also numerous operas and orchestras. The Brazilian conductor Antônio Carlos Gomes became internationally known with operas such as Il Guarany. At the end of the 19th century, orchestrated dramaturgias were accompanied with songs of famous artists such as the conductress Chiquinha Gonzaga. Already in the early 20th century there was the presence of theaters, entrepreneurs and actor companies. In 1940, Paschoal Carlos Magno and his student's theater, the comedians group and the Italian actors Adolfo Celi, Ruggero Jacobbi and Aldo Calvo, founders of the Teatro Brasileiro de Comédia, renewed the Brazilian theater. From the 1960s, it was attended by a theater dedicated to social and religious issues. The most prominent authors at this stage were Jorge Andrade and Ariano Suassuna.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.